European Partnership for Alternative Approaches to Animal Testing Working Group 2 Progress Report Pr

1
European Partnership for AlternativeApproaches
to Animal TestingWorking Group 2 - Progress
ReportPrioritisation, Promotion and
Implementation of Future ResearchJuergen
Buesing, Hennicke Kamp
2
WG 2 - Remit

• Identification of priorities for future 3R
  orientated research
• Identification of gaps and opportunities to
  improve animal welfare through reduction,
  refinement and replacement
• Collate and exchange knowledge from different
  industry sectors, Commission, regulatory bodies
  and academia
• Interaction with other working groups in order to
  accelerate development, validation and acceptance
  of alternative methods

3
WG 2 - Contributors

• Co-chairs
• Juergen Buesing (DG RTD)
• Hennicke Kamp (BASF)

• Team Members
• Abbott
• BASF
• Bayer
• Covance
• ECVAM
• GSK
• Henkel
• Intervet

• Lilly
• LOréal
• Pfizer
• PG
• Phenion
• Syngenta
• Unilever

4
WG 2 - Prioritisation

• Based on
• Likelihood to deliver animal welfare benefits
• Overall feasibility
• Already ongoing work
• Required resources

5
WG 2 will identify gaps and emerging
opportunities in 3Rs research

• Address research needs
• Initiate research to develop novel approaches to
  safety testing
• Provide innovative thinking

• Action 1Novel strategies for Reproductive /
  Developmental Toxicity
• Based on ILSI/HESI project on agrochemical safety
  testing (ACSA)
• Reduction, Refinement

6
WG 2, Action 1 Cross Sector Cooperation A
First Major Success
7
WG 2, Action 1 Cross Sector Cooperation A
First Major Success

• Expert Workshop
• Nov 14th, 2006, hosted by BASF
• gt 30 experts (Commission, industry sectors,
  regulatory bodies)
• Transfer to other industry sectors possible?

• Extended one generation study applicable for
  REACH
• Reduction of animal numbers possible by gt 40
• Modifications to protocol necessary
• Validation needed (with WG 5)
• ECVAM lead (close collaboration with US EPA)
• Experimental work conducted by BASF, Bayer,
  Syngenta
• OECD guideline possible just in time for REACH

8

• WG 2 will
• serve as a platform for experts to exchange
  knowledge and coordinate research activities

• Bring together experts
• Optimise research strategies and resource use
• Give input to public funding programmes and
  jointly collate financial resources

• Action 2Repeat Systemic Dose Toxicity
• Replacement

9
WG 2, Action 2 Creating New Thinking in
Toxicology
10
WG 2 represents one of five interlinked issues
within EPAA and will

• Use input of WG 1 and of WG 4
• Optimise research activities through discussion
  with experts
• Give input to WG 3, WG 4, WG 5 and ECVAM

• Joint Meeting with WG 1 on Dec 6th
• Identification of opportunities
• Monitor progress of research activities

11
Summary

• Action 1 Strategies for Reproductive Toxicity
  Testing
• Reduction, Refinement
• Next step validation study (WG 5)
• Action 2 Repeat Systemic Dose Toxicity
• Replacement
• Next step set up research framework
• Joint Meeting with WG 1
• Make use of mapping to prioritise research
• Upcoming Action 3 (to be started Q2/2007)

12
Future Actions

• Action 4 Group Sizes in Toxicological Testing
• Reduction
• Foreseen to be started Q3/2007
• Action 5 In Vitro Metabolism
• Replacement
• Foreseen to be started early 2008

13
Working Group 2 - Progress ReportJuergen
Buesing, Hennicke KampThank You!